Immix Biopharma | Investor Presentation Deck | 64 slides · page 15 of 64
The slide highlights a significant difference in neurotoxicity percentages (4% vs 23-28%) and CRS onset/duration metrics.
Deck · comparison_table · compare_peers · overcrowded density
Slide locked Sign in to view
Slide schematic 6/6
callout 1/1 chart 1/1 source-note 1/1 table 1/1 title 2/2
Components 6
primary bar-vertical source-note data action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1